BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Would Use Strain Substitution To Prevent Superbugs
Executive Summary
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.